文献速递临床试验与 GCP医学人工智能与信息学

基于人工智能筛选个体接受补充磁共振成像在人群乳腺癌筛查中的随机试验:ScreenTrustMRI 试验

AI-based selection of individuals for supplemental MRI in population-based breast cancer screening: the randomized ScreenTrustMRI trial.
PubMed 文献 · Nat Med · 2024-07-08

ScreenTrustMRI 随机临床试验对筛查乳腺X线摄影阴性且AI评分高(前6.9%)的个体随机分组,接受或不接受补充MRI。补充MRI检出癌症数为每1000次MRI检查64例,传统乳腺密度方法为16.5例,多数额外检出癌症为浸润性且部分为多灶性,使每检出癌症成本与筛查乳腺X线摄影相当。

要点

  • AI评分前6.9%的筛查乳腺X线摄影阴性个体被随机分入补充MRI组或不接受MRI组。
  • 补充MRI每1000次检查检出64例癌症,传统乳腺密度方法为16.5例。
  • 多数额外检出癌症为浸润性,部分为多灶性,提示检出及时。

核心结论

  • 使用AI评分筛选小部分(6.9%)乳腺X线摄影阴性个体接受补充MRI可检出许多漏诊癌症,使每检出癌症成本与筛查乳腺X线摄影相当。

研究设计与样本

  • ScreenTrustMRI随机临床试验,对筛查乳腺X线摄影阴性且AI评分高(前6.9%)的个体随机分组,接受补充MRI组与不接受MRI组。
  • 主要终点为晚期乳腺癌,定义为间期癌、浸润成分大于15 mm或淋巴结阳性癌症,基于从初次筛查起27个月随访。
  • 次要终点包括补充MRI检出的癌症,为本文重点,按研究方案在主要结局前预设报告。

主要发现

  • 补充MRI每1000次MRI检查检出癌症64例,传统乳腺密度方法为16.5例,AI方法效率接近四倍。
  • 多数额外检出的癌症为浸润性,部分为多灶性,提示其检出及时。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Screening mammography reduces breast cancer mortality, but studies analyzing interval cancers diagnosed after negative screens have shown that many cancers are missed. Supplemental screening using magnetic resonance imaging (MRI) can reduce the number of missed cancers. However, as qualified MRI staff are lacking, the equipment is expensive to purchase and cost-effectiveness for screening may not be convincing, the utilization of MRI is currently limited. An effective method for triaging individuals to supplemental MRI screening is therefore needed. We conducted a randomized clinical trial, ScreenTrustMRI, using a recently developed artificial intelligence (AI) tool to score each mammogram. We offered trial participation to individuals with a negative screening mammogram and a high AI score (top 6.9%). Upon agreeing to participate, individuals were assigned randomly to one of two groups: those receiving supplemental MRI and those not receiving MRI. The primary endpoint of ScreenTrustMRI is advanced breast cancer defined as either interval cancer, invasive component larger than 15 mm or lymph node positive cancer, based on a 27-month follow-up time from the initial screening. Secondary endpoints, prespecified in the study protocol to be reported before the primary outcome, include cancer detected by supplemental MRI, which is the focus of the current paper. Compared with traditional breast density measures used in a previous clinical trial, the current AI method was nearly four times more efficient in terms of cancers detected per 1,000 MRI examinations (64 versus 16.5). Most additional cancers detected were invasive and several were multifocal, suggesting that their detection was timely. Altogether, our results show that using an AI-based score to select a small proportion (6.9%) of individuals for supplemental MRI after negative mammography detects many missed cancers, making the cost per cancer detected comparable with screening mammography. ClinicalTrials.gov registration: NCT04832594 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Salim M, Liu Y, Sorkhei M, et al. AI-based selection of individuals for supplemental MRI in population-based breast cancer screening: the randomized ScreenTrustMRI trial. Nat Med. 2024. PMID: 38977914. doi:10.1038/s41591-024-03093-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。